Verixa Event Tracker · India · US · EU · Leads

🔄 Patent-filing date realignment · 18 Jun → 26 Jun → 03 Jul 2026
Patent FD shifted 15 Jun 202626 Jun 2026 03 Jul 2026. Public marketing unlocks Mon 29 Jun 2026 Tue 07 Jul 2026 (W5) via dual gate: patent counsel clearance + compliance gate (Contractor onboarded OR Interim-Vimal mitigations live). Event speaker submissions + CFP entries continue uninterrupted — those are internal application activities, not public claims. Booth + sponsor commitments remain gated on Sep-01 Verified-Go-Live Decision.
📝 Thought-leadership two-step · ISPE (primary) → ECA (secondary) · decided 20 Jun 2026
① PRIMARY — ISPE Pharmaceutical Engineering Feature (durable, citable credibility asset; lower promotional risk pre-pilot). Action now: send the editor query to PEmag@ispe.org (request GAMP ERB pre-submission discussion). Full manuscript via ScholarOne (mc.manuscriptcentral.com/ispe-pe) only on editor invitation. Gates: Vimal go-ahead + Public Claim Register sign-off; original/unpublished; GREEN disclosure. Doc: Verixa_Publications/ISPE_PharmaEng_2026_Feature_Proposal_2026-06-20.md.
② SECONDARY — ECA 2nd Annex 22 / AI Conference (E-EU-01) · 7-8 Oct 2026 Copenhagen · pitch as a narrowed working session, not an overview. Gates (all must hold before sending): (a) ISPE query in + originality cleared; (b) content materially distinct from ISPE manuscript; (c) do NOT circulate ECA slides publicly before ISPE accepts; (d) confirm ECA still accepts 2026 external speakers. Doc: Verixa_Publications/ECA_Annex22_2026_Speaker_Proposal_2026-06-20.md.
Open verification before publishing either: EU AI Act high-risk reasoning → confirm with EU regulatory counsel.
India + US + EU pharma conferences · conclaves · webinars · founder speaker / panel posture pre-W14 · booth/sponsor only post-Sep-01 Verified-Go-Live · owner: Vimal · prepared 2026-06-18 · enriched 2026-06-18 with verixa_event_research
53
Events tracked (IN·US·EU·GBL)
21
HIGH-ROI events
5
Urgent / time-sensitive
8
Webinar tracks
FY27
Booth/sponsor window

🚨 Urgent / time-sensitive — act this week

💡 Insights & Top-5 highest-leverage targets

📅 Action plan timeline (from verixa_event_research · synced to Marketing Plan §16)

Now → Mon 30 Jun 2026
ETPharma outreach for Jul 24 panel · send ISPE editor query (AIPM poster — DROPPED 20 Jun)
ET Pharma Tech Conclave · ISPE
Jul 2026
India thought-leadership sprint: "Schedule M + AI governance + Annex 22 readiness"
ET Pharma · iPHEX · CII Pharma Summit
Aug 2026
Submit FDLI Annual 2027 CFP (opens 17 Aug) · pitch KENX webinar collaboration
FDLI · KENX
Sep–Oct 2026
No-booth private-meeting posture at PDA/FDA · iPHEX · Veeva US · AIPM
PDA/FDA · iPHEX · Veeva US · AIPM
Nov 2026
EU intelligence + BD sprint via partneringONE® and EU GMP/QC labs
BIO-Europe · PharmaLab · CPHI Worldwide · Frontiers Health
Jan–Apr 2027
US manufacturing / validation messaging · Cologne EU intel feed
INTERPHEX · FDLI · DIA Europe · BIO-Europe Spring
May–Jul 2027
CDMO + QMS private-meeting campaign across Veeva EU + CPHI Americas + Bio-IT World
Veeva Europe · CPHI Americas · Bio-IT World · DIA Global · BIO International
All
🚨 Urgent
Tier 1
Tier 2
Tier 3
Webinar
CFP open / due soon
All regions
🇮🇳 India
🇺🇸 US
🇪🇺 EU
🌐 Global / Online
click column headers to sort
India + US + EU Pharma Event Circuit · Jul 2026 → Jul 2027
ID Event Region Tier ROI Window Location Audience / Why Verixa Posture CFP / Deadline Status Owner Notes
Founder personal-membership applications (P0 · no spend gate)
BodyRegionMembership tierWhat it unlocksStatusOwner
ISPE International (HQ Tampa) + India AffiliateGLOBALIndividual professional memberIndia Pharma 4.0 + US Annual Meeting speaker pool · Pharma Engineering journal · CSV/Annex 22 communityTO APPLYVimal
Indian Pharmaceutical Alliance (IPA)INDIAAssociate / personalIndia Pharma annual · state pharma conclaves (UP, Telangana, Gujarat) · panel slotsTO APPLYVimal
PDA (Parenteral Drug Association) + India ChapterGLOBALIndividual memberData integrity / Annex 11 / Part 11 / AI-in-QMS audience · QA Head + RA reach · global PDA chapters + PDA/FDA Joint Regulatory Conference invite trackTO APPLYVimal
RAPS (Regulatory Affairs Professionals Society)GLOBALIndividual memberRAPS Convergence + Euro Convergence + Live Online + Global RA communityTO APPLYVimal
DIA (Drug Information Association)GLOBALIndividual / professionalDIA Global Annual + DIA Europe + regional eventsTO APPLYVimal
FDLI (Food and Drug Law Institute)USIndividual memberFDLI Annual Conference + Enforcement/Litigation/Compliance Conference + CFP trackTO APPLYVimal
Pharmexcil (export promotion council)INDIAAssociate/personaliPHEX 2026 + Pharmexcil exporter network + private-meeting access via Department of CommerceTO APPLYVimal
IDMA + OPPI (India)INDIAAssociate / personalIndia SME pharma + multinational subsidiaries · member-only forums · trade pressTO APPLYVimal
Posture & Spend Rules (locked from Marketing Plan §11 + Appendix I)
Speaker · Founder-only · Vimal abstract via Droupathy first-draft · Contractor (or Interim-Vimal + external counsel) clears regulatory claims · zero spend gate.
Panel · Founder or Janani · same compliance review path · zero spend gate.
Poster · AIPM-style · founder + Janani · technical posters reviewed by Contractor / external counsel for claim discipline.
Private breakfast / executive briefing / DCAT-style private meetings · Founder + Janani · target-account-curated · venue-only spend · pre-launch posture.
Webinar · Founder-led + Droupathy producer · Verixa-hosted or invited · subject to Public Claim Register pre-publish.
Booth / sponsor · GATED on Sep-01 Verified-Go-Live Decision passing · NOT allowed pre-Sep-01 · revisit Q4 2026 for Q1-Q2 2027 events.
'; dl("Verixa_Status_"+FILE.replace(/\.html?$/,"")+"_"+new Date().toISOString().slice(0,10)+".doc", new Blob([''+h],{type:"application/msword"})); } function exportText(){ var s=snapshot(); var sec=""; var L=["VERIXA — STATUS SNAPSHOT","Source: "+TITLE,"Generated: "+stamp(), "Completed: "+s.counts["Completed"]+" | In Progress: "+s.counts["In Progress"]+" | Not Started: "+s.counts["Not Started"]+" | Unset: "+s.counts["—"],""]; s.rows.forEach(function(r){ if(r.section!==sec){sec=r.section;L.push("");L.push("== "+sec+" ==");} L.push(" ["+r.status+"] "+r.id+(r.title?" — "+r.title:"")); }); dl("Verixa_Status_"+FILE.replace(/\.html?$/,"")+"_"+new Date().toISOString().slice(0,10)+".txt", new Blob([L.join("\n")],{type:"text/plain;charset=utf-8"})); } function buttons(){ if(document.getElementById("vxstatus-bar")) return; var bar=document.createElement("div"); bar.id="vxstatus-bar"; bar.style.cssText="position:fixed;right:16px;bottom:16px;z-index:9999;display:flex;gap:8px"; function mk(label,fn){var b=document.createElement("button");b.textContent=label; b.style.cssText="background:#FFE388;color:#2a2200;border:none;border-radius:18px;padding:9px 14px;font-size:12.5px;font-weight:700;cursor:pointer;box-shadow:0 2px 10px rgba(0,0,0,.4)"; b.addEventListener("click",fn);return b;} bar.appendChild(mk("⤓ Word",exportWord)); bar.appendChild(mk("⤓ Text",exportText)); document.body.appendChild(bar); } function run(){enhance();buttons();} if(document.readyState==="loading"){document.addEventListener("DOMContentLoaded",run);}else{run();} var obs=new MutationObserver(function(muts){ for(var i=0;i